INKT News

The IPO market remained active this past week as seven IPOs raised $2.1 billion. SPAC activity kept steady with 10 blank check IPOs raising $1.6 billion. New filers continued to pour into the IPO pipeline, with 12 IPOs and nine SPACs submitting initial filings. Software development platform GitLab (GTLB) priced above the upwardly revised range to raise $801...read more

MiNK Therapeutics, a Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases, raised $40 million by offering 3.3 million shares at $12, the low end of the range of $12 to $14. The company offered 0.7 million fewer shares than anticipated. MiNK Therapeutics' lead program, AGENT-797, is an allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell...read more

MiNK Therapeutics, a Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases, announced terms for its IPO on Tuesday. The New York, NY-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, MiNK Therapeutics would command a fully diluted market value of $493 million. MiNK...read more

The IPO market was full steam ahead this past week as 11 IPOs came to market. SPAC activity remained steady with seven blank check IPOs. New filers continue to pour into the IPO pipeline, with 15 IPOs and eight SPACs submitting initial filings. Tech consultancy Thoughtworks (TWKS) raised $774 million at a $7.0 billion market cap. This agile software developer...read more